- Home
- ANVS vs IKNA Comparison
ANVS vs IKNA Comparison
Compare ANVS & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- IKNA
- Stock Information
- Founded
- ANVS 2008
- IKNA 2016
- Country
- ANVS United States
- IKNA United States
- Employees
- ANVS N/A
- IKNA N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- IKNA Health Care
- Exchange
- ANVS Nasdaq
- IKNA Nasdaq
- Market Cap
- ANVS 92.6M
- IKNA 81.6M
- IPO Year
- ANVS 2020
- IKNA 2021
- Fundamental
- Price
- ANVS $2.13
- IKNA $1.39
- Analyst Decision
- ANVS Strong Buy
- IKNA Buy
- Analyst Count
- ANVS 6
- IKNA 2
- Target Price
- ANVS $31.40
- IKNA $3.00
- AVG Volume (30 Days)
- ANVS 684.1K
- IKNA 167.1K
- Earning Date
- ANVS 03-31-2025
- IKNA 03-11-2025
- Dividend Yield
- ANVS N/A
- IKNA N/A
- EPS Growth
- ANVS N/A
- IKNA N/A
- EPS
- ANVS N/A
- IKNA N/A
- Revenue
- ANVS N/A
- IKNA $659,000.00
- Revenue This Year
- ANVS N/A
- IKNA N/A
- Revenue Next Year
- ANVS N/A
- IKNA N/A
- P/E Ratio
- ANVS N/A
- IKNA N/A
- Revenue Growth
- ANVS N/A
- IKNA N/A
- 52 Week Low
- ANVS $2.08
- IKNA $1.22
- 52 Week High
- ANVS $20.00
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- ANVS 18.43
- IKNA 43.10
- Support Level
- ANVS $2.08
- IKNA $1.40
- Resistance Level
- ANVS $2.79
- IKNA $1.53
- Average True Range (ATR)
- ANVS 0.32
- IKNA 0.06
- MACD
- ANVS -0.06
- IKNA 0.00
- Stochastic Oscillator
- ANVS 2.08
- IKNA 28.57
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.